Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 14/20 | 0.51 |
| ▸ | PPARG | P37231 | 3/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | MMP8 | P22894 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18597892 | 0.82 | MME (0.48) | MMEPPARGPPARANPSR1 | |
| SCHEMBL14890510 | 0.82 | MME (0.48) | MMEPPARGPPARANPSR1 | |
| SCHEMBL20376371 | 0.81 | MME (0.42) | MMEPPARGPPARAMMP2MMP3 | |
| SCHEMBL14902382 | 0.75 | MME (0.50) | MME | |
| SCHEMBL18386378 | 0.74 | MME (0.43) | MMEPPARGPPARAMMP2MMP3 | |
| SCHEMBL18597988 | 0.72 | PPARG (0.46) | MMEPPARGPPARANPSR1EPHX2 | |
| SCHEMBL16939261 | 0.69 | MME (0.55) | MME | |
| SCHEMBL11969895 | 0.69 | MME (0.52) | MMEPPARGPPARAMMP8EPHX2 | |
| SCHEMBL14919221 | 0.69 | MME (0.52) | MMEPPARGPPARAMMP8EPHX2 | |
| SCHEMBL11727313 | 0.69 | CA12 (0.47) | PPARGPPARANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12016835-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2024-06-25 | — | — | US | disclosed |
| US-20230285340-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-09-14 | — | — | US | disclosed |
| US-20180194718-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-07-12 | — | — | US | disclosed |
| US-20170368010-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-12-28 | — | — | US | disclosed |
| US-9840460-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-12-12 | — | — | US | disclosed |
| US-20170327459-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285340-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885PPARG 4731/4885PPARA 4574/4885 |
| US-20170368010-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885PPARG 4731/4885PPARA 4574/4885 |
| US-20180194718-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885PPARG 4847/4885PPARA 4838/4885 |
| US-20170327459-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885PPARG 4847/4885PPARA 4838/4885 |
| US-12016835-B2 | Neprilysin inhibitors | MME, REN, ACE | MME 1/4885PPARG 4731/4885PPARA 4574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.